The safety and tolerability of multiple and ascending doses of the triple receptor agonist of GLP-1, GIP, and glucagon LY3437943 was evaluated in 72 subjects with type 2 diabetes during 12 wk of treatment in a phase 1 double-blind, randomized, multicenter study. The gene discussed is GIP; the disease is type 2 diabetes mellitus.